Spruce Biosciences, Inc., a late-stage biopharmaceutical company specializing in therapies for neurological disorders, has announced its return to trading on the Nasdaq Capital Market. The company’s shares resumed trading today under the ticker symbol “SPRB,” following a brief hiatus.
Based in South San Francisco, Spruce Biosciences is committed to addressing significant unmet medical needs in the field of neurology. With a focus on developing innovative treatment options, the company is actively working on novel therapies designed to improve patient outcomes in this critical area of healthcare.
Investors and stakeholders can stay informed about the company’s ongoing initiatives and updates by visiting its official website or engaging with its social media platforms, including X, LinkedIn, Facebook, and YouTube.
For further inquiries, Spruce Biosciences has provided contact details for its media and investor relations teams. Interested parties can reach out via the provided email addresses for additional information or to engage in discussions about the company’s developments and strategies.
This resumption of trading marks a significant step for Spruce Biosciences, as it seeks to expand its presence in the biopharmaceutical landscape while continuing to work towards innovative solutions for patients in need.
